The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The prognostic value of HER2 gene dosage and heterogeneity at a single-cell resolution in gastroesophageal adenocarcinoma.
 
Yashika Parashar
No Relationships to Disclose
 
Leigh Culnane
No Relationships to Disclose
 
Joshua Remland
No Relationships to Disclose
 
Chetan Nambiar
No Relationships to Disclose
 
Chen Yuan
No Relationships to Disclose
 
Shagun Nasta
No Relationships to Disclose
 
Adam Bard
No Relationships to Disclose
 
Haeseong Park
Consulting or Advisory Role - Merck
Research Funding - Amgen (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); D3Bio (Inst); Exelixis (Inst); Huoata Bio (Inst); Idience (Inst); Incyte (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Strata Oncology (Inst); Tizona Therapeutics, Inc. (Inst)
Travel, Accommodations, Expenses - Amgen
 
Samuel Klempner
Honoraria - Merck Serono
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; BeiGene; Daiichi Sankyo/UCB Japan; Eisai; I-Mab; Merck; Novartis; SERVIER; Taiho Oncology
Research Funding - Arcus Biosciences (Inst); BeiGene (Inst); I-Mab (Inst); Leap Therapeutics (Inst); Mersana (Inst)
Other Relationship - Clinical Care Options; NCCN; Research to Practice
(OPTIONAL) Uncompensated Relationships - Debbies Dream Foundation; Hope for Stomach Cancer
 
Marios Giannakis
Consulting or Advisory Role - AsteaZeneca; ChromaCode; Nerviano Medical Sciences; OncLive
Research Funding - Janssen
Travel, Accommodations, Expenses - Dava Oncology
 
Andrew Aguirre
Stock and Other Ownership Interests - Kestrel Therapeutics; Riva Therapeutics
Honoraria - Phillips Gilmore Oncology
Consulting or Advisory Role - Alcon (I); Arrakis Therapeutics; AstraZeneca; Boehringer Ingelheim; Merck; Mirati Therapeutics; Nimbus Therapeutics; Plexium; Revolution Medicines; Riva Therapeutics; SERVIER; Syros Pharmaceuticals; T-Knife; Third Rock Ventures
Research Funding - Bristol-Myers Squibb/Celgene; Deerfield Management; Mirati Therapeutics; Novartis; Novo Ventures; Revolution Medicines; Syros Pharmaceuticals
 
Kimmie Ng
Honoraria - Seagen
Consulting or Advisory Role - Abbvie; Bayer; CytomX Therapeutics; GlaxoSmithKline; Jazz Pharmaceuticals; Pfizer; Revolution Medicines
Research Funding - Evergrande Group (Inst); Janssen (Inst); Pharmavite (Inst)
Expert Testimony - Crico
Other Relationship - jama
 
Jeffrey Meyerhardt
Employment - Dana-Farber Cancer Institute; Newton Wellesley Hospital (I)
Research Funding - Boston Biomedical (Inst)
 
Brian Wolpin
Consulting or Advisory Role - Agenus; EcoR1 Capital; GRAIL; Ipsen; Mirati Therapeutics; Revolution Medicines; Third Rock Ventures
Research Funding - AstraZeneca (Inst); Harbinger Health (Inst); Lilly (Inst); Novartis (Inst); Revolution Medicines (Inst)
 
Rona Yaeger
Consulting or Advisory Role - Loxo@Lilly; Mirati Therapeutics; Revolution Medicines
Research Funding - Boehringer Ingelheim (Inst); Boundless Bio (Inst); Daiichi Sankyo/UCB Japan (Inst); Mirati Therapeutics (Inst); Pfizer (Inst)
 
James Cleary
Honoraria - AstraZeneca; Blueprint Medicines; Gilead Sciences; Incyte; Syros Pharmaceuticals
Research Funding - Amgen; Apexigen; Arcus Biosciences; Arcus Biosciences; AstraZeneca; Bayer; BMS (Inst); BMS (Inst); Esperas Pharma; Merck; Merus (Inst); Roche/Genentech (Inst); SERVIER (Inst); Tesaro
Travel, Accommodations, Expenses - Agios; Bristol-Myers Squibb; Gilead Sciences; Incyte; Roche
 
Charlotte Wang
Speakers' Bureau - Thermo Fisher Scientific
 
Peter Enzinger
Consulting or Advisory Role - ALX Oncology; Amgen; Arcus Biosciences; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Celgene; Chimeric Therapeutics; Chimeric Therapeutics; Coherus Biosciences; Daiichi Sankyo; Eisai; Henlius; IDEAYA Biosciences; ImmPACT Bio; Legend Biotech; Legend Biotech; Lilly; loxo; Loxo; Merck; Novartis; Oncolys BioPharma; Ono Pharmaceutical; Regeneron; Sanofi; SERVIER; Taiho Oncology; Taiho Pharmaceutical; Takeda; Takeda; Turning Point Therapeutics; Turning Point Therapeutics; Xencor; Xencor; Zymeworks
 
Nilay Sethi
Consulting or Advisory Role - Astrin Biosciences
Patents, Royalties, Other Intellectual Property - Compositions and methods for treating and/or identifying an agent for treating intestinal cancers 63/208313 filed 6/8/2021
 
Harshabad Singh
Honoraria - UpToDate
Consulting or Advisory Role - Dewpoint Therapeutics; Merck
Speakers' Bureau - Peerdirect
Research Funding - AstraZeneca/Daiichi Sankyo
Travel, Accommodations, Expenses - Dava Oncology